Vanguard National Trust’s Biogen BIIB Stock Holding History

Vanguard National Trust’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$66.5K	Sell	308 -36	-10%	-$6.89K	﹤0.01%	393
2026 Q1	$63.1K	Buy	+344	New	+$63.4K	﹤0.01%	374

Other funds holding BIIB

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Vanguard National Trust's BIIB Position: Q2 2026 in Review

Vanguard National Trust reduced its Biogen (BIIB) stake by 10% in Q2 2026, selling an estimated $6.89K and leaving 308 shares worth $66.5K. The position accounts for ﹤0.01% of the portfolio, ranked #393.

Vanguard National Trust first reported a position in BIIB in Q1 2026 and has held it in 2 quarters since. 1,032 funds tracked by Wall St. Rank hold BIIB as of Q2 2026.

Vanguard National Trust held 308 shares of Biogen worth $66.5K as of Q2 2026.
Vanguard National Trust sold 36 Biogen shares in Q2 2026, an estimated $6.89K.
Biogen made up ﹤0.01% of Vanguard National Trust's portfolio in Q2 2026, its #393 holding.
Vanguard National Trust first reported a position in Biogen in Q1 2026 and has held it in 2 quarters since.
1,032 funds tracked by Wall St. Rank held Biogen as of Q2 2026.

Based on Vanguard National Trust's 13F filing for Q2 2026, filed 13 Aug 2026.